CXCR4 in clinical hematology.

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• CXCR4 is crucial for stem cell and leukocyte localization.
• Pharmacological targeting of CXCR4 has clinical applications in stem cell mobilization.
• Plerixafor inhibits CXCL12 binding to CXCR4.

Purpose of the Study:

• To review the clinical utility of CXCR4 inhibition, specifically with plerixafor.
• To highlight plerixafor's efficacy in stem cell mobilization for transplantation.
• To explore potential therapeutic applications of CXCR4 inhibition in various diseases.

Main Methods:

• Clinical data review of plerixafor use in stem cell mobilization.
• Preclinical data analysis for CXCR4 inhibition in disease models.
• Evaluation of plerixafor's effects on neutrophils and tumor cells.

Main Results:

• Plerixafor plus G-CSF enhances stem cell mobilization for autologous transplantation in multiple myeloma and lymphoma patients.
• Plerixafor is being investigated for allogeneic transplantation and enhancing chemotherapy effectiveness in AML and CLL.
• Plerixafor may restore neutrophil counts in chronic neutropenias and has potential in other diseases.

Conclusions:

• CXCR4 inhibition with plerixafor is a valuable strategy for stem cell mobilization.
• Plerixafor demonstrates broad therapeutic potential across hematologic malignancies and other inflammatory and infectious diseases.
• Further clinical development is warranted for CXCR4 inhibitors in diverse medical conditions.